STOCK TITAN

Amneal Pharmaceuticals (AMRX) Co-CEO gains 6.38M shares in Kashiv acquisition

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. reported that Co-CEO and director Chintu Patel, through limited liability companies he manages, indirectly acquired 6,381,734 shares of Class A Common Stock on August 10, 2026. This equity was received as part of Amneal’s acquisition of Kashiv BioSciences, LLC, alongside cash consideration and other share issuances. Following this transaction, Patel also holds 1,388,521 shares directly and 24,753,252 shares indirectly through family trusts.

Positive

  • None.

Negative

  • None.
Insider Patel Chintu
Role Co-CEO
Type Security Shares Price Value
Grant/Award Class A Common Stock F1 6,381,734 -- --
holding Class A Common Stock -- -- --
holding Class A Common Stock -- -- --
Holdings After Transaction: Class A Common Stock — 6,381,734 shares (Indirect, By Limited Liability Companies); Class A Common Stock — 1,388,521 shares (Direct); Class A Common Stock — 24,753,252 shares (Indirect, By Family Trusts)
Footnotes (1)
  1. F1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.
Shares received by managed LLCs 6,381,734 shares of Class A Common Stock Equity consideration to limited liability companies managed by Chintu Patel in the Kashiv acquisition on August 10, 2026
Cash consideration for Kashiv $375,000,000 Aggregate cash consideration for 100% of Kashiv BioSciences membership interests, subject to purchase price adjustments
Total shares issued as Kashiv consideration 28,942,098 shares of Class A Common Stock Share component of consideration for Kashiv BioSciences acquisition
Direct holdings after transaction 1,388,521 shares of Class A Common Stock Shares directly held by Chintu Patel following the reported transactions
Indirect family trust holdings 24,753,252 shares of Class A Common Stock Shares held indirectly by Chintu Patel through family trusts after the reported transactions
Membership Interest Purchase Agreement financial
"pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026"
A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.
purchase price adjustments financial
"for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments"
Purchase price adjustments are changes made to the agreed sale price of a company after closing to reflect actual financial facts—like cash on hand, debts, or inventory—found when final accounts are prepared. Think of it as the final bill after a home inspection: the buyer and seller settle differences so the price matches reality. For investors, these adjustments affect the true cost, future earnings and cash flow from a deal, and therefore the value of the investment.
Class A Common Stock financial
"and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock)"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
Family Trusts financial
"total_shares_following_transaction 24,753,252.0000, nature_of_ownership By Family Trusts"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did AMRX Co-CEO Chintu Patel report in this Form 4 transaction?

Co-CEO Chintu Patel reported an indirect acquisition of 6,381,734 shares of Amneal Class A Common Stock on August 10, 2026, received by limited liability companies he manages as part of the Kashiv BioSciences acquisition.

How many AMRX shares did entities managed by Chintu Patel receive in the Kashiv deal?

Limited liability companies managed by Chintu Patel received 6,381,734 shares of Amneal Class A Common Stock. These shares formed part of the equity consideration paid in Amneal’s acquisition of Kashiv BioSciences, LLC under a Membership Interest Purchase Agreement.

What were the total consideration terms in Amneal’s acquisition of Kashiv BioSciences (AMRX)?

Amneal’s subsidiary acquired Kashiv for $375,000,000 in cash, subject to purchase price adjustments, plus 28,942,098 shares of Amneal Class A Common Stock. A portion of these shares, 6,381,734, went to limited liability companies managed by Chintu Patel.

What are Chintu Patel’s direct and indirect AMRX share holdings after this filing?

After the reported transactions, Chintu Patel holds 1,388,521 shares of Amneal Class A Common Stock directly and 24,753,252 shares indirectly through family trusts, in addition to 6,381,734 shares held indirectly via limited liability companies he manages.

Is the AMRX Form 4 transaction a market purchase or part of an acquisition?

The Form 4 entry reflects an acquisition-related equity issuance, not a market trade. The 6,381,734 shares were issued to limited liability companies managed by Chintu Patel as consideration in Amneal’s purchase of Kashiv BioSciences, LLC.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Chintu

(Last)(First)(Middle)
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Co-CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/10/2026A(1)6,381,734A(1)6,381,734IBy Limited Liability Companies
Class A Common Stock1,388,521D
Class A Common Stock24,753,252IBy Family Trusts
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.
Remarks:
/s/ Denis Butkovic, Attorney-in-Fact08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)